Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients...
Brief Summary
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Intervention(s) in this Clinical Trial
- Drug: Tamuslosin
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients with urination disorder not accompanied by apparent organic or neurologic abnormality(lower urinary tract syndrome: LUTs)．
Exclusion Criteria:
- Patients with urination disorder accompanied by apparent organic or neurologic abnormality, active urinary tract infections, severe cardiovascular, hepatic and/or kidney complications.
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 20 Years
Maximum Age for this Clinical Trial: 90 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: Astellas Pharma Inc Industry
Overall Clinical Trial Officials and Contacts
Study Director Study Chair Clinical Development, Astellas Pharma Inc.
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00239265
Study ID Number: B6171/LCT2
ClinicalTrials.gov Identifier: NCT00239265
Health Authority: Japan: Ministry of Health, Labor and Welfare
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00239265
